Prevalence of antibodies to SARS-CoV-2 in healthy blood donors in New York

- 3 Kathy Kamath¹, Elisabeth Baum-Jones¹, Gregory Jordan¹, Winston Haynes¹, Rebecca Waitz¹, John Shon¹, Steve
- 4 Kujawa¹, Lyn Fitzgibbons², Debra Kessler³, Larry Luchsinger³, Yale IMPACT Team⁴, Patrick Daugherty¹
- 6 ¹ Serimmune, Inc., 150 Castilian Dr, Suite 100, Goleta, CA 93117 USA
- ² Santa Barbara Cottage Hospital, 2400 Bath St., Santa Barbara, CA 93105 USA
- 8 ³ New York Blood Center 310 East 67th St., New York, NY 10065 USA
- 9 ⁴ Yale University School of Medicine 60 College St., New Haven, CT 06510 USA
- 11 Corresponding author: Kathy Kamath
- 12 Email: kathy@serimmune.com

1

2

5

10

14

- 13 Telephone: +1 (805) 448-6529
- 15 Members of the Yale IMPACT Team⁴
- 16 Kelly Anastasio, Michael H. Askenase, Maria Batsu, Santos Bermejo, Kristina Brower, Molly L. Bucklin, Staci Cahill,
- 17 Melissa Campbell, Yiyun Cao, Arnau Casanovas-Massana, Rupak Datta, Giuseppe Deluliis, Charles Dela Cruz,
- 18 Rebecca Earnest, Shelli Farhadian, John Fournier, Bertie Geng, Nathan Grubaugh, Ryan Handoko, Akiko Iwasaki,
- 19 William Khoury-Hanold, Lynda Knaggs, Albert Ko, Maxine Kuang, Sarah Lapidus, Anjelica Martin, Irene Matos,
- 20 David McDonald, Maksym Minasyan, Adam J. Moore, M. Catherine Muenker, Nida Naushad, Allison Nelson,
- 21 Jessica Nouws, Angela Nunez, Hong-Jai Park, Xiaohua Peng, Tyler Rice, Kadi-Ann Rose, Lorenzo Sewanan, Lokesh
- 22 Sharma, Denise Shepard, Mikhail Smolgovsky, Nicole Sonnert, Yvette Strong, Codruta Todeasa, Jordan Valdez,
- 23 Sofia Velazquez, Pavithra Vijayakumar, Elizabeth B. White, Anne L. Wyllie

ABSTRACT

Despite the high level of morbidity and mortality worldwide, there is increasing evidence for asymptomatic carriers of the novel coronavirus SARS-CoV-2. We analyzed blood specimens from 1,559 healthy blood donors, collected in the greater New York metropolitan area between the months of March and July 2020 for antibodies to SARS-CoV-2 virus. Using our proprietary technology, SERA (Serum Epitope Repertoire Analysis), we observed a significant increase in SARS-CoV-2 seropositivity rates over the four-month period, from 0% [95% CI: 0 - 1.5%] (March) to 11.6% [6.0 - 21.2%] (July). Follow-up ELISA tests using S1 and nucleocapsid viral proteins confirmed most of these results. Our findings are consistent with seroprevalence studies within the region and with reports that SARS-COV-2 infections can be asymptomatic or cause only mild symptoms.

IMPORTANCE

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has caused vast morbidity and mortality worldwide, yet several studies indicate that there may be a significant number of infected people who are asymptomatic or exhibit mild symptoms. In this study, samples were collected from healthy blood donors in a region of rapidly increasing disease burden (New York metropolitan area) and we hypothesized that a subset would be seropositive to SARS-CoV-2. People who experienced mild or no symptoms during SARS-CoV-2 infection may represent a source for convalescent plasma donors.

OBSERVATION

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has exerted high morbidity worldwide, with mortality rates reported greater than 10% for some age groups [1]. Yet several studies have indicated that there may be a significant number of people who are asymptomatic or exhibit mild symptoms [2 - 4], including in the New York metropolitan region [5, 6]. We developed an assay to detect IgG and IgM antibodies to SARS-CoV-

2 virus and analyzed plasma samples from healthy blood donors collected during the early months of the pandemic in that region.

Development of SERA assay for antibodies to SARS-CoV-2

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

Our technology, Serum Epitope Repertoire Analysis (SERA) enables discovery and semi-quantitative detection of antibody epitopes with high resolution that can be mapped to eliciting antigens and organisms. The SERA assay platform has been described in detail elsewhere [7], but briefly, it utilizes a random bacterial display 12-mer peptide library of 10¹⁰ diversity in conjunction with NGS to collect and sequence the set of peptides that represent an individual's serological antibody epitope repertoire. The shared epitopes targeted by antibody repertoires are then identified by custom bioinformatics algorithms [8], using cohort-based subtractive analysis of the mimotope repertoires. For the development of SERA panels to detect IgG and IgM antibodies against SARS-CoV-2, serum samples from confirmed COVID-19 patients (positive for SARS-CoV-2 nucleic assay testing (NAT)) were acquired from the Yale IMPACT biorepository and the Santa Barbara Cottage Hospital (Santa Barbara, CA) in accordance with BRISQ guidelines [9] and the SBCH IRB. The majority of subjects were hospitalized and serum samples were collected between 0 and 57 days post symptom onset. For the discovery of SARS-CoV-2 IgG and IgM antibody epitope motifs, we applied SERA to a Discovery cohort of 164 COVID-19 samples, and 430 (for IgM panel) and 497 (for IgG panel) pre-pandemic healthy controls (Table S1). The resulting epitope motifs were compiled into IgG and IgM panels, and the enrichment of each panel motif was normalized and summed to generate a composite diagnostic score [7]. A seropositivity cut-off value of 25 was established to yield a specificity of > 99% for either panel. In an independent verification set of 250 COVID-19 specimens for which we had days since symptom onset data, the sensitivity of SERA IgG and IgM at >10 days post symptom onset was ≥ 91% (Figure 1). In a cohort of 1,500 pre-pandemic samples, the specificity of the SERA SARS-CoV-2 IgG panel was 99.3% and the IgM panel was 99.1%; the specificity of the IgG and IgM panels together was 98.7%.

Sample collection from healthy blood donors

We initiated a collaboration with Blood Centers of America to collect plasma from healthy donors throughout the US with a primary objective of increasing our healthy subject cohort. Collection and screening began in New York at the New York Blood Center (NYBC) in March 2020. Individuals who were suspected of having COVID-19 were deferred from donation for 14 days after resolution of symptoms. For this study, a total of 1,559 whole blood samples from healthy blood donors were sent to our laboratory within 2 weeks of collection, in seven shipments. The demographics of these samples are shown in **Table S2**. Upon arrival at our laboratory, blood plasma was isolated, screened by SERA assay and the results were uploaded to the epitope repertoire database.

Prevalence of antibodies to SARS-CoV-2 in blood donors

For each sample analyzed using the SERA assay, the epitope repertoires are compiled into a database that enables assessment of any previously or future developed disease-specific SERA panel, without the need to re-test the sample. We applied the SARS-CoV-2 IgG panel retrospectively to samples collected during the period March 1 through July 7, 2020. Of 1,559 blood samples processed, a total of 68 had IgG antibodies against SARS-CoV-2 on the SERA assay. As collection proceeded, the seropositive rate increased from 0% [95% CI: 0 - 1.5%] to 11.6% [6.0 - 21.2%] (Figure 2, Table S3). Eighty-four percent (57/68) of these samples were also positive for IgG antibodies to SARS-CoV-2 Spike S1 and nucleocapsid proteins by follow-up ELISAs (Supplemental Text 1), providing independent verification of the presence of a SARS-CoV-2 antibody response in these subjects.

Because the age of donors were not equally distributed amongst the sample shipments, we interrogated whether age or shipment date was a stronger predictor of the seropositivity observed. GLM regression analysis of SARS-CoV-2 seropositivity relative to donor age or shipment date revealed that sample shipment date contributed more significantly (p=5.5e-8) to the prediction of seropositivity than age (p=0.35) (**Supplemental Figure 1**).

Concluding remarks

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115116117

118

119

This study provides insight into trends of rate of seropositivity to SARS-CoV-2 among asymptomatic blood donors

in the metropolitan New York area during the early months of the COVID-19 pandemic but was not designed to

measure population-wide seroprevalence. Nonetheless, our results were consistent with reports that a significant

number of SARS-CoV-2 infected people in this region may be asymptomatic or present with mild symptoms [5, 6].

Here we demonstrated the utility of SERA for serosurveillance studies of emerging infections through

retrospective analysis of archived data in populations. Previously collected data was simply re-analyzed for SARS-

CoV-2 associated epitopes, thus mitigating the need to store samples or perform additional assays in a surveillance

setting. In addition, the new panel was applied retrospectively in silico to large pre-pandemic cohorts in panel

development and verification phases, demonstrating high specificity without the need to perform additional

immunoassays. Finally, applying the panel to cohorts afforded the opportunity to identify subjects with

presumptive asymptomatic or mild disease for research purposes amongst the blood donor population from New

York and surrounding areas.

Our results raise the question of whether a larger number of convalescent plasma donors could be identified

among healthy, asymptomatic donors. However, there is concern about providing antibody results to blood

donors without an improved understanding of their immunological significance. We also demonstrate the utility

of SERA for monitoring the antibody response to emerging infections.

REFERENCES

1. Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.

Lancet Infect Dis. 2020; 20:e238-e244


120 2. Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus 121 infections (COVID-19). Int J Infect Dis. 2020: 94:154-155 122 3. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus 123 disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro 124 Surveill. 2020; 25:2000180 125 4. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United 126 States, March 23-May 12, 2020 [published online ahead of print, 2020 Jul 21]. JAMA Intern Med. 2020; 127 10.1001/jamainternmed.2020.4130. doi:10.1001/jamainternmed.2020.4130 128 5. Rosenberg ES, Tesoriero JM, Rosenthal EM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 129 infection in New York [published online ahead of print, 2020 Jun 17]. Ann Epidemiol. 2020; \$1047-2797(20)30201-5 130 131 6. Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, Teo C, Arunkumar GA, McMahon M, 132 Jhang J, Nowak MD, Simon V, Sordillo EM, van Bakel H, Krammer F. Seroconversion of a city: Longitudinal 133 monitoring of SARS-CoV-2 seroprevalence in New York City. MedRxiv. [Preprint] July 28, 2020. Available 134 from https://doi.org/10.1101/2020.6.28.20142190 135 7. Kamath K, Reifert J, Johnston T, et al. Antibody epitope repertoire analysis enables rapid antigen discovery 136 and multiplex serology. Sci Rep. 2020; 10:5294 137 8. Pantazes RJ, Reifert J, Bozekowski J, Ibsen KN, Murray JA, Daugherty PS. Identification of disease-specific 138 motifs in the antibody specificity repertoire via next-generation sequencing. Sci Rep. 2016; 6:30312. 139 9. Moore HM, Kelly AB, Jewell SD, et al. Biospecimen reporting for improved study quality (BRISQ). J 140 Proteome Res. 2011; 10:3429-3438 141 142

FIGURES

144

145


Figure 1



148 Figure 2

146

147






Figure S1




FIGURE LEGENDS

Figure 1: Performance SERA assay to detect IgG and IgM antibodies to SARS-CoV-2. SERA IgG+IgM performance on a validation cohort of SARS-CoV-2 NAT+ patients. The maximum SERA score for IgG or IgM is shown. Samples above a cutoff of 25 are classified as seropositive. COVID-19 cases are indicated by days post symptom onset. Panel sensitivity at the specified time intervals are shown above each group. Specificity on a cohort of 1,500 prepandemic controls was 99.3% for IgG, 99.1% for IgM, 98.7% for IgG or IgM, and 100% if a case was positive for IgG and IgM (no pre-pandemic validation controls were positive for both IgG and IgM concomitantly).

Figure 2. Seropositivity rate of SARS-CoV-2 based on SERA IgG increases over time in healthy, asymptomatic blood donors. A) SERA SARS-CoV-2 IgG scores and B) percentage of samples that were SARS-CoV-2 IgG positive

from healthy blood donors by shipment date. Error bars in (B) represent 95% CI using Wilson score. Shipment dates are shown on the x-axis; blood samples were collected within 2 weeks prior to shipment. Each shipment included 245-250 subjects except the final shipment (n = 69).

Supplemental Figure S1: SARS-CoV-2 seropositivity vs. shipment date for each specimen. GLM regression analysis of seropositivity to SARS-CoV-2 relative to the age of the patient and the shipment date of the sample. Shipment date contributed more significantly (p=5.5e-8) to the prediction of seropositivity than age (p=0.35). When we performed the same regression for SARS-CoV-2 seropositivity against age alone, the age coefficient was significant (p=5.5e-5). Similarly, regression for SARS-CoV-2 seropositivity against shipment date alone yielded a highly significant shipment date coefficient (p=1.0e-9). These results suggest that shipment date, not the age bias, is the dominant factor contributing to the increased positivity rates.

SUPPLEMENTAL MATERIALS

Supplemental Text 1: Spike and Nucleocapsid protein ELISA. For confirmatory ELISA testing, 50 μL of SARS-CoV-2 Spike S1 or nucleocapsid recombinant proteins (ACROBiosystems cat# S1N-C52H3 and NUN-C5227) were coated on ELISA plates at 0.5 μg/mL. Plates were blocked with 5% nonfat dry milk (NFDM) in PBS followed by incubation with plasma diluted 1:250 in PBS. Wells were washed 3X with PBS with 0.1% tween20 (PBST) and incubated with anti-human IgG conjugated to HRP (Jackson Immuno Research labs cat# 109-035-088) at 1:10,000. Wells were washed 4X with PBST and developed with TMB solution. Cut-off values for ELISAs were established based on 400 pre-pandemic controls.

Table S1: Sample cohorts for discovery and verification of SARS-CoV-2 epitope motif panels

		COVID-19 Disease Severity				
	Sample Cohort	Asymp	Mild/ Moderate	Severe	Moderate or Severe*	Total n
Discovery Set	Confirmed COVID-19 (Yale IMPACT)	5	103	45	11	164
	Pre-pandemic controls	-	-	-	-	430 (IgM) or 497 (IgG)
Verification Set	Confirmed COVID-19 (Yale IMPACT)	8	20	17	143	191
	Confirmed COVID-19 (SBCH)	4	54	22	-	81
	Mayo Clinic pre-pandemic controls	-	-	-	-	1,500

^{*}Subjects were hospitalized but intubation status was not known

Table S2: Demographics of Healthy Blood Donors

Donor c	Donor characteristics n		%
Corr	Female	755	48
Sex	Male	804	52
	17-25	395	25
	26-35	200	13
	36-45	164	11
Age	46-55	206	13
	56-65	370	24
	66-80	224	14
	White	396	25
	Black	350	22
Race	Hispanic/Latino	454	29
	Asian/Pacific Islander	358	23
	Other	1	0.1

Table S3. Blood donor samples analyzed and prevalence of seropositive samples per shipment

Shipment Date	Number of Samples in Shipment	Number of Seropositive Samples	Proportion of Seropositive Samples (95% CI)
3/12/2020	250	0	0% (0 - 1.5%)
3/26/2020	250	2	0.8% (0.2 - 2.9%)
4/16/2020	249	5	2.0% (0.9 - 4.6%)
5/28/2020	247	15	6.1% (3.7 - 9.8%)
6/10/2020	249	20	8.0% (5.3 - 12.0%)
6/24/2020	245	18	7.3% (4.7 - 11.3%)
7/9/2020	69	8	11.6% (6.0 - 21.2%)
All shipments	1,559	68	

FOOTNOTE PAGE

Conflict of interest statement

- Serimmune employees (K.K., E.B.J., G.J., W.H., R.W., J.S., S.K., P.D.) receive salary and stock options from
- 212 Serimmune.

203

204

205206

207208209

210

211

213

214

215

Funding statement

- SARS-CoV-2 sample collection and curation by the Yale IMPACT team was supported by the Yale COVID-19
- resource research fund.